메뉴 건너뛰기




Volumn 70, Issue 17, 2010, Pages 6902-6912

Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; DRUG METABOLITE; ICT 2552; ICT 2588; ILOMASTAT; INTERSTITIAL COLLAGENASE; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT; ANGIOGENESIS INHIBITOR; COLCHICINE; MATRIX METALLOPROTEINASE; OLIGOPEPTIDE; THIOUREA;

EID: 77956279673     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-1440     Document Type: Article
Times cited : (50)

References (46)
  • 1
    • 33845286942 scopus 로고    scopus 로고
    • Vascular disrupting agents
    • Lippert JW III. Vascular disrupting agents. Bioorg Med Chem 2007;15:605-15.
    • (2007) Bioorg Med Chem , vol.15 , pp. 605-615
    • Lippert III, J.W.1
  • 2
    • 65549164757 scopus 로고    scopus 로고
    • Microtubule depolymerizing vascular disrupting agents: Novel therapeutic agents for oncology and other pathologies
    • Kanthou C, Tozer GM. Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies. Int J Exp Pathol 2009;90:284-94.
    • (2009) Int J Exp Pathol , vol.90 , pp. 284-294
    • Kanthou, C.1    Tozer, G.M.2
  • 3
    • 0037115398 scopus 로고    scopus 로고
    • ZD6126: A novel vascular-targeting agent that causes selective destruction of tumor vasculature
    • Davis PD, Dougherty GJ, Blakey DC, et al. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 2002;62:7247-53.
    • (2002) Cancer Res , vol.62 , pp. 7247-7253
    • Davis, P.D.1    Dougherty, G.J.2    Blakey, D.C.3
  • 5
    • 34247249906 scopus 로고    scopus 로고
    • Vascular disrupting agents in clinical development
    • DOI 10.1038/sj.bjc.6603694, PII 6603694
    • Hinnen P, Eskens FA. Vascular disrupting agents in clinical development. Br J Cancer 2007;96:1159-65. (Pubitemid 46625071)
    • (2007) British Journal of Cancer , vol.96 , Issue.8 , pp. 1159-1165
    • Hinnen, P.1    Eskens, F.A.L.M.2
  • 6
    • 33645728030 scopus 로고    scopus 로고
    • Promise of new vascular-disrupting agents balanced with cardiac toxicity: Is it time for oncologists to get to know their cardiologists?
    • van Heeckeren WJ, Bhakta S, Ortiz J, et al. Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists? J Clin Oncol 2006;24:1485-8.
    • (2006) J Clin Oncol , vol.24 , pp. 1485-1488
    • Van Heeckeren, W.J.1    Bhakta, S.2    Ortiz, J.3
  • 7
    • 1642494772 scopus 로고    scopus 로고
    • Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer
    • Cooney MM, Radivoyevitch T, Dowlati A, et al. Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res 2004;10:96-100.
    • (2004) Clin Cancer Res , vol.10 , pp. 96-100
    • Cooney, M.M.1    Radivoyevitch, T.2    Dowlati, A.3
  • 9
    • 0036512208 scopus 로고    scopus 로고
    • New functions for the matrix metalloproteinases in cancer progression
    • Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74. (Pubitemid 37328786)
    • (2002) Nature Reviews Cancer , vol.2 , Issue.3 , pp. 161-174
    • Egeblad, M.1    Werb, Z.2
  • 10
    • 33644545381 scopus 로고    scopus 로고
    • Tumour microenvironment - Opinion: Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy
    • Overall CM, Kleifeld O. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006;6:227-39.
    • (2006) Nat Rev Cancer , vol.6 , pp. 227-239
    • Overall, C.M.1    Kleifeld, O.2
  • 14
    • 15244352321 scopus 로고    scopus 로고
    • Membrane type-matrix metalloproteinases and tumor progression
    • Sounni NE, Noel A. Membrane type-matrix metalloproteinases and tumor progression. Biochimie 2005;87:329-42.
    • (2005) Biochimie , vol.87 , pp. 329-342
    • Sounni, N.E.1    Noel, A.2
  • 15
    • 0036109679 scopus 로고    scopus 로고
    • MT-MMPs play pivotal roles in cancer dissemination
    • DOI 10.1023/A:1015527220537
    • Yana I, Seiki M. MT-MMPs play pivotal roles in cancer dissemination. Clin Exp Metastasis 2002;19:209-15. (Pubitemid 34555419)
    • (2002) Clinical and Experimental Metastasis , vol.19 , Issue.3 , pp. 209-215
    • Yana, I.1    Seiki, M.2
  • 16
    • 0037426578 scopus 로고    scopus 로고
    • Membrane-type 1 matrix metalloproteinase: A key enzyme for tumor invasion
    • Seiki M. Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Lett 2003;194:1-11.
    • (2003) Cancer Lett , vol.194 , pp. 1-11
    • Seiki, M.1
  • 17
    • 77049106382 scopus 로고    scopus 로고
    • Proteolytic and non-proteolytic roles of membrane type-1 matrix metalloproteinase in malignancy
    • Strongin AY. Proteolytic and non-proteolytic roles of membrane type-1 matrix metalloproteinase in malignancy. Biochim Biophys Acta 2010;1803:133-41.
    • (2010) Biochim Biophys Acta , vol.1803 , pp. 133-141
    • Strongin, A.Y.1
  • 18
    • 44349156127 scopus 로고    scopus 로고
    • MT1-MMP is required for efficient tumor dissemination in experimental metastatic disease
    • DOI 10.1038/sj.onc.1210982, PII 1210982
    • Szabova L, Chrysovergis K, Yamada SS, Holmbeck K. MT1-MMP is required for efficient tumor dissemination in experimental metastatic disease. Oncogene 2008;27:3274-81. (Pubitemid 351733384)
    • (2008) Oncogene , vol.27 , Issue.23 , pp. 3274-3281
    • Szabova, L.1    Chrysovergis, K.2    Yamada, S.S.3    Holmbeck, K.4
  • 19
    • 14944357237 scopus 로고    scopus 로고
    • Membrane-type-1 matrix metalloproteinase confers tumorigenicity on nonmalignant epithelial cells
    • Soulie P, Carrozzino F, Pepper MS, Strongin AY, Poupon MF, Montesano R. Membrane-type-1 matrix metalloproteinase confers tumorigenicity on nonmalignant epithelial cells. Oncogene 2005;24:1689-97.
    • (2005) Oncogene , vol.24 , pp. 1689-1697
    • Soulie, P.1    Carrozzino, F.2    Pepper, M.S.3    Strongin, A.Y.4    Poupon, M.F.5    Montesano, R.6
  • 20
    • 33847133438 scopus 로고    scopus 로고
    • Fibroblast-derived MT1-MMP promotes tumor progression in vitro and in vivo
    • DOI 10.1186/1471-2407-6-52
    • Zhang W, Matrisian LM, Holmbeck K, Vick CC, Rosenthal EL. Fibroblast-derived MT1-MMP promotes tumor progression in vitro and in vivo. BMC Cancer 2006;6:52. (Pubitemid 46277066)
    • (2006) BMC Cancer , vol.6 , pp. 52
    • Zhang, W.1    Matrisian, L.M.2    Holmbeck, K.3    Vick, C.C.4    Rosenthal, E.L.5
  • 21
    • 22244472310 scopus 로고    scopus 로고
    • Retroviral gene transfer of an antisense construct against membrane type 1 matrix metalloproteinase reduces the invasiveness of rheumatoid arthritis synovial fibroblasts
    • Rutkauskaite E, Volkmer D, Shigeyama Y, et al. Retroviral gene transfer of an antisense construct against membrane type 1 matrix metalloproteinase reduces the invasiveness of rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2005;52:2010-4.
    • (2005) Arthritis Rheum , vol.52 , pp. 2010-2014
    • Rutkauskaite, E.1    Volkmer, D.2    Shigeyama, Y.3
  • 22
    • 9444290419 scopus 로고    scopus 로고
    • Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP
    • Sabeh F, Ota I, Holmbeck K, et al. Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. J Cell Biol 2004;167:769-81.
    • (2004) J Cell Biol , vol.167 , pp. 769-781
    • Sabeh, F.1    Ota, I.2    Holmbeck, K.3
  • 23
    • 0346363608 scopus 로고    scopus 로고
    • Sequence-specific silencing of MT1-MMP expression suppresses tumor cell migration and invasion: Importance of MT1-MMP as a therapeutic target for invasive tumors
    • Ueda J, Kajita M, Suenaga N, Fujii K, Seiki M. Sequence-specific silencing of MT1-MMP expression suppresses tumor cell migration and invasion: importance of MT1-MMP as a therapeutic target for invasive tumors. Oncogene 2003;22:8716-22.
    • (2003) Oncogene , vol.22 , pp. 8716-8722
    • Ueda, J.1    Kajita, M.2    Suenaga, N.3    Fujii, K.4    Seiki, M.5
  • 24
    • 20344361933 scopus 로고    scopus 로고
    • Metalloproteinases and their inhibitors in tumor angiogenesis
    • Handsley MM, Edwards DR. Metalloproteinases and their inhibitors in tumor angiogenesis. Int J Cancer 2005;115:849-60.
    • (2005) Int J Cancer , vol.115 , pp. 849-860
    • Handsley, M.M.1    Edwards, D.R.2
  • 25
    • 60649108677 scopus 로고    scopus 로고
    • Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis
    • Devy L, Huang L, Naa L, et al. Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res 2009;69:1517-26.
    • (2009) Cancer Res , vol.69 , pp. 1517-1526
    • Devy, L.1    Huang, L.2    Naa, L.3
  • 26
    • 18344366604 scopus 로고    scopus 로고
    • MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression
    • Sounni NE, Devy L, Hajitou A, et al. MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression. FASEB J 2002;16:555-64.
    • (2002) FASEB J , vol.16 , pp. 555-564
    • Sounni, N.E.1    Devy, L.2    Hajitou, A.3
  • 28
    • 0036041236 scopus 로고    scopus 로고
    • Bioreductively activated antitumor N-oxides: The case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy
    • Patterson LH. Bioreductively activated antitumor N-oxides: the case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy. Drug Metab Rev 2002;34:581-92.
    • (2002) Drug Metab Rev , vol.34 , pp. 581-592
    • Patterson, L.H.1
  • 29
    • 39749101689 scopus 로고    scopus 로고
    • Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: Results of a phase I study
    • Albertella MR, Loadman PM, Jones PH, et al. Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study. Clin Cancer Res 2008;14:1096-104.
    • (2008) Clin Cancer Res , vol.14 , pp. 1096-1104
    • Albertella, M.R.1    Loadman, P.M.2    Jones, P.H.3
  • 30
    • 14844303761 scopus 로고    scopus 로고
    • Capecitabine: A review
    • Walko CM, Lindley C. Capecitabine: a review. Clin Ther 2005;27:23-44.
    • (2005) Clin Ther , vol.27 , pp. 23-44
    • Walko, C.M.1    Lindley, C.2
  • 31
    • 41649103896 scopus 로고    scopus 로고
    • Tumour endoproteases: The cutting edge of cancer drug delivery?
    • Atkinson JM, Siller CS, Gill JH. Tumour endoproteases: the cutting edge of cancer drug delivery? Br J Pharmacol 2008;153:1344-52.
    • (2008) Br J Pharmacol , vol.153 , pp. 1344-1352
    • Atkinson, J.M.1    Siller, C.S.2    Gill, J.H.3
  • 32
    • 16744368637 scopus 로고    scopus 로고
    • United Kingdom Co-Ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia
    • second edition
    • Workman P, Twentyman P, Balkwill F, et al. United Kingdom Co-Ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer 1998;77:1-10.
    • (1998) Br J Cancer , vol.77 , pp. 1-10
    • Workman, P.1    Twentyman, P.2    Balkwill, F.3
  • 33
    • 34447293780 scopus 로고    scopus 로고
    • Membrane type matrix metalloproteinases (MMPs) show differential expression in non-small cell lung cancer (NSCLC) compared to normal lung: Correlation of MMP-14 mRNA expression and proteolytic activity
    • Atkinson JM, Pennington CJ, Martin SW, et al. Membrane type matrix metalloproteinases (MMPs) show differential expression in non-small cell lung cancer (NSCLC) compared to normal lung: correlation of MMP-14 mRNA expression and proteolytic activity. Eur J Cancer 2007;43:1764-71.
    • (2007) Eur J Cancer , vol.43 , pp. 1764-1771
    • Atkinson, J.M.1    Pennington, C.J.2    Martin, S.W.3
  • 34
    • 0037359601 scopus 로고    scopus 로고
    • Elevated membrane-type matrix metalloproteinases in gliomas revealed by profiling proteases and inhibitors in human cancer cells
    • Nuttall RK, Pennington CJ, Taplin J, et al. Elevated membrane-type matrix metalloproteinases in gliomas revealed by profiling proteases and inhibitors in human cancer cells. Mol Cancer Res 2003;1:333-45.
    • (2003) Mol Cancer Res , vol.1 , pp. 333-345
    • Nuttall, R.K.1    Pennington, C.J.2    Taplin, J.3
  • 35
    • 77956296475 scopus 로고    scopus 로고
    • MMP activated vascular disrupting agents
    • Gill JH, Loadman P, Falconer RA, Patterson LH, Atkinson JM, Bibby MC inventors; University of Bradford, applicant. UK patent WO2008125800. October 23
    • Gill JH, Loadman P, Falconer RA, Patterson LH, Atkinson JM, Bibby MC inventors; University of Bradford, applicant. MMP activated vascular disrupting agents. UK patent WO2008125800. 2008 October 23.
    • (2008)
  • 36
    • 0021061819 scopus 로고
    • Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
    • Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63. (Pubitemid 14203433)
    • (1983) Journal of Immunological Methods , vol.65 , Issue.1-2 , pp. 55-63
    • Mosmann, T.1
  • 37
    • 35148827486 scopus 로고    scopus 로고
    • Auristatin PYE, a novel synthetic derivative of dolastatin 10, is highly effective in human colon tumour models
    • Shnyder SD, Cooper PA, Millington NJ, Pettit GR, Bibby MC. Auristatin PYE, a novel synthetic derivative of dolastatin 10, is highly effective in human colon tumour models. Int J Oncol 2007;31:353-60.
    • (2007) Int J Oncol , vol.31 , pp. 353-360
    • Shnyder, S.D.1    Cooper, P.A.2    Millington, N.J.3    Pettit, G.R.4    Bibby, M.C.5
  • 38
    • 0032499266 scopus 로고    scopus 로고
    • Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: An examination of the subsite pocket
    • Yamamoto M, Tsujishita H, Hori N, et al. Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket. J Med Chem 1998;41:1209-17.
    • (1998) J Med Chem , vol.41 , pp. 1209-1217
    • Yamamoto, M.1    Tsujishita, H.2    Hori, N.3
  • 39
    • 0032842567 scopus 로고    scopus 로고
    • Tumor targeting with a selective gelatinase inhibitor
    • Koivunen E, Arap W, Valtanen H, et al. Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol 1999;17:768-74.
    • (1999) Nat Biotechnol , vol.17 , pp. 768-774
    • Koivunen, E.1    Arap, W.2    Valtanen, H.3
  • 40
    • 0026742089 scopus 로고
    • The influence of hydralazine on the vasculature, blood perfusion and chemosensitivity of MAC tumours
    • Quinn PK, Bibby MC, Cox JA, Crawford SM. The influence of hydralazine on the vasculature, blood perfusion and chemosensitivity of MAC tumours. Br J Cancer 1992;66:323-30.
    • (1992) Br J Cancer , vol.66 , pp. 323-330
    • Quinn, P.K.1    Bibby, M.C.2    Cox, J.A.3    Crawford, S.M.4
  • 41
    • 0023935131 scopus 로고
    • Validation of the fluorescent dye Hoechst 33342 as a vascular space marker in tumours
    • Smith KA, Hill SA, Begg AC, Denekamp J. Validation of the fluorescent dye Hoechst 33342 as a vascular space marker in tumours. Br J Cancer 1988;57:247-53. (Pubitemid 18096329)
    • (1988) British Journal of Cancer , vol.57 , Issue.3 , pp. 247-253
    • Smith, K.A.1    Hill, S.A.2    Begg, A.C.3    Denekamp, J.4
  • 42
    • 49149106418 scopus 로고    scopus 로고
    • Dimerization of endogenous MT1-MMP is a regulatory step in the activation of the 72-kDa gelatinase MMP-2 on fibroblasts and fibrosarcoma cells
    • Ingvarsen S, Madsen DH, Hillig T, et al. Dimerization of endogenous MT1-MMP is a regulatory step in the activation of the 72-kDa gelatinase MMP-2 on fibroblasts and fibrosarcoma cells. Biol Chem 2008;389:943-53.
    • (2008) Biol Chem , vol.389 , pp. 943-953
    • Ingvarsen, S.1    Madsen, D.H.2    Hillig, T.3
  • 43
    • 9944223360 scopus 로고    scopus 로고
    • Correlation of tumor- and stromal-derived MT1-MMP expression with progression of human ovarian tumors in SCID mice
    • Drew AF, Blick TJ, Lafleur MA, et al. Correlation of tumor- and stromal-derived MT1-MMP expression with progression of human ovarian tumors in SCID mice. Gynecol Oncol 2004;95:437-48.
    • (2004) Gynecol Oncol , vol.95 , pp. 437-448
    • Drew, A.F.1    Blick, T.J.2    Lafleur, M.A.3
  • 44
    • 34249744576 scopus 로고    scopus 로고
    • Crosstalk between neovessels and mural cells directs the site-specific expression of MT1-MMP to endothelial tip cells
    • Yana I, Sagara H, Takaki S, et al. Crosstalk between neovessels and mural cells directs the site-specific expression of MT1-MMP to endothelial tip cells. J Cell Sci 2007;120:1607-14.
    • (2007) J Cell Sci , vol.120 , pp. 1607-1614
    • Yana, I.1    Sagara, H.2    Takaki, S.3
  • 45
    • 34948862788 scopus 로고    scopus 로고
    • Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel
    • Martinelli M, Bonezzi K, Riccardi E, et al. Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel. Br J Cancer 2007;97:888-94.
    • (2007) Br J Cancer , vol.97 , pp. 888-894
    • Martinelli, M.1    Bonezzi, K.2    Riccardi, E.3
  • 46
    • 62549085978 scopus 로고    scopus 로고
    • A mathematical model of doxorubicin penetration through multicellular layers
    • Evans CJ, Phillips RM, Jones PF, et al. A mathematical model of doxorubicin penetration through multicellular layers. J Theor Biol 2009;25:598-608.
    • (2009) J Theor Biol , vol.25 , pp. 598-608
    • Evans, C.J.1    Phillips, R.M.2    Jones, P.F.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.